AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE in women ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory submissions.

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

announced on February 28 that a trial train arrived at Cuffe Parade, the final station of Mumbai's first underground Metro line, Metro Line 3 or Aqualine. This, MMRC said, this marks a crucial step ...

A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...

The strength of evidence is solid, supported by the multicenter phase II trial design, which included a substantial ... tumor size <2 cm but with high Ki-67 level or histologic grade 3. Clinical and ...

provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial ...

The proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit. HealthDay News — One in 6 patients in phase 2 clinical cancer trials ...

One of biotech’s best-fund­ed star­tups has just raised a huge new round to take its lead drug in­to fi­nal-stage test­ing.